Tiaojing Cuyun Wan
Shop NowOverview
What is Tiaojing Cuyun Wan?
Tiaojing Cuyun Wan is an 18-herb proprietary Traditional Chinese Medicine (TCM) herbal formula traditionally used to regulate menstrual cycles and support reproductive health, particularly when periods are delayed or scant.
Product Information
| Chinese name | 调经促孕丸 |
|---|---|
| Pinyin | Tiao Jing Cu Yun Wan |
| Brand | Tong Ren Tang |
| China Drug Approval No. | Z11020027 |
| Dosage form | pill |
| Traditional function | Warm the kidney and strengthen the spleen; invigorate blood and regulate menstruation. |
| Strength | 100 pills weigh 10 g |
| Individual package | 5g*10sachets |
| Recommended use | For clinician-assessed menstrual irregularity, absent or painful periods, or infertility within the pattern specified on the label. |
| GTIN | 6904579876834 |
Evidence at a Glance
Human studies mainly assess this medicine added to conventional treatment. Some report improved fertility-related outcomes, but study limitations, combination treatment and review overlap prevent firm conclusions about benefit or safety when used alone.
The label advises against use with excessive menstrual bleeding or the TCM pattern called yin deficiency with exuberant fire. Adverse reactions and contraindications are not clearly established.
Uses
Common Uses
Tiaojing Cuyun Wan is commonly used for concerns such as:
- Delayed, infrequent or absent periods.
- Light menstrual flow or periods with blood clots.
- Lower abdominal pain with a cold sensation during periods.
- Difficulty becoming pregnant over a prolonged period.
- Cold sensations and pain in the lower back and knees.
Traditional & Labeled Uses
温肾健脾，活血调经。
Warm the kidney and strengthen the spleen; invigorate blood and regulate menstruation.
- Menstrual irregularity
- Absent periods
- Painful periods
- Infertility
The manufacturer’s indications are distinct from modern clinical trial findings. Studies in selected infertility populations do not establish benefit for every labeled symptom or justify adding PCOS as a general product indication.
Understanding the TCM Perspective
The label specifies spleen and kidney yang deficiency with obstruction by blood stasis. These are traditional diagnostic patterns, not diagnoses of kidney disease, spleen disease or a blood-clotting disorder. Pattern assessment requires an appropriately trained clinician.
Related TCM Patterns
Tiaojing Cuyun Wan is classified as a prescription medicine in China. This Learn information is for educational purposes only. Always consult a healthcare provider before starting TCM treatments.
Safety
Pregnancy
The accessible product instructions do not establish safety during pregnancy or provide a pregnancy-specific regimen. Fertility-related use does not establish safety after conception; ask the treating clinician before continuing if pregnancy is suspected or confirmed.
Allergy
The formula contains 18 ingredients, including animal-derived pilose antler. Product-specific allergy instructions were not identified; ingredient tolerability requires individual review.
Breastfeeding
Product-specific breastfeeding safety information was not identified.
Younger Users
A pediatric dose and product-specific safety evidence for younger users were not identified.
Drug Interactions
A validated product-specific interaction list was not identified. Combination use in clinical studies does not establish compatibility with all medicines; have the prescribed regimen reviewed by the treating clinician.
When to Seek Medical Advice
This is a prescription medicine. Seek clinical assessment for absent periods, persistent difficulty conceiving, or excessive menstrual bleeding; the label advises against use with excessive bleeding. Discuss suspected pregnancy and any new symptoms during treatment with the prescriber.
Contraindications
- The official instructions state that contraindications are not clearly established.
- Label precaution: not suitable for people with excessive menstrual bleeding or the TCM pattern of yin deficiency with exuberant fire.
Reported Adverse Reactions
- The official instructions state that adverse reactions are not clearly established.
Evidence
Human Clinical Evidence
Clinical observation of Tiaojing Cuyun Pills combined with dydrogesterone in treatment of infertility due to luteal insufficiency
Adding Tiaojing Cuyun Pills to dydrogesterone improved uterine lining thickness and composite clinical response compared with dydrogesterone alone. The study did not separately report pregnancy rates.
Meta-analysis of Tiaojing Cuyun Wan combined with Western medicine for infertility associated with obesity-related polycystic ovary syndrome
Adding Tiaojing Cuyun Pills to conventional medicines was associated with higher pregnancy and ovulation rates than conventional medicines alone. Endometrial thickness and adverse-event rates did not differ significantly.
Network meta-analysis of Chinese patent medicines combined with clomiphene for ovulatory infertility
Tiaojingcuyun Pills plus clomiphene ranked highest for pregnancy rate among the regimens compared. Limited trial quality and indirect comparisons make that ranking uncertain.
Verification
PRODUCT IDENTITY
- Brand Name
- Tong Ren Tang
- Chinese Name
- 同仁堂
- Manufacturer
- Beijing Tong Ren Tang Co., Ltd.
- China drug approval number
- Z11020027
- Prescription status in China
- Prescription medicine.
These are Chinese product-registration details. They do not establish approval or availability in another country.
Verified by the AuthHerb Verification Team
- Brand relationship confirmed
- Manufacturer legal name confirmed
- Approval number confirmed
- Current packaging matched
- Registration holder / manufacturer checked
- Authenticity method checked
- Label/source evidence recorded
Ingredients
The linked Tiaojing Cuyun Wan formula lists 18 ingredients. The first six ingredients are shown below.
- Curculigo rhizome — 仙茅
- Dipsacus root — 续断
- Chinese dodder seed — 菟丝子
- Goji fruit — 枸杞子
- Chinese raspberry fruit — 覆盆子
- Chinese yam — 山药
Official Label Dosage
Take 5 g (50 pills) orally and twice daily
Follow the current package insert if its instructions differ.
Individual package: 5g*10sachets
Missed Dose Information
No product-specific missed-dose instruction was identified.
Additional Directions
Start on day 5 of the menstrual cycle and take for 20 consecutive days. If there is no menstrual cycle, take for 20 days each month. The labeled course is three months, or as directed by the physician.
Follow the prescribing clinician’s instructions. Store sealed. The manufacturer describes water-honey pills and lists a 48-month shelf life; check the actual pack’s expiry date.
A purchase option’s quantity does not define how long you should take the medicine.
Frequently Asked Questions About Tiaojing Cuyun Wan
The label lists menstrual irregularity, absent or painful periods, and infertility within the specified TCM pattern. Symptoms include delayed or scanty periods, menstrual blood clots, cold lower abdominal pain during periods, prolonged absence of periods, and cold painful lower back and knees.
The selected studies mainly examine it with conventional medicines. Their findings do not establish that it improves fertility when used alone, and live-birth benefit remains unestablished in the accessible evidence.
The manufacturer’s dose is 5 g (50 pills) twice daily. Start on cycle day 5 for 20 consecutive days; without a cycle, take for 20 days each month. The labeled course is three months or as directed by the physician.
Pregnancy safety and a pregnancy-specific regimen were not established in the accessible product instructions. Ask the treating clinician before continuing if pregnancy is suspected or confirmed.
The label advises against use with excessive menstrual bleeding or the TCM pattern called yin deficiency with exuberant fire. Its contraindications and adverse reactions are listed as not clearly established.
It contains pilose antler and therefore is not an entirely plant-based formula.
The official webpage identifies a 5 g sachet but does not establish the total sachet count for the intended retail pack. Confirm the actual pack before purchase or publication.
References
-
[1]Clinical observation of Tiaojing Cuyun Pills combined with dydrogesterone in treatment of infertility due to luteal insufficiency
Population: Women aged 22–36 with infertility attributed to luteal insufficiency
Indication: Infertility due to luteal insufficiency
Intervention: Tiaojing Cuyun Pills 5 g twice daily plus dydrogesterone
Comparison: Dydrogesterone alone
Sample size: 82 (41 per group)
Duration: 3 months
Reported findings
Adding Tiaojing Cuyun Pills to dydrogesterone improved uterine lining thickness and composite clinical response compared with dydrogesterone alone. The study did not separately report pregnancy rates.
Interpretation
Combination-treatment evidence only; the composite response must not be described as a pregnancy rate.
Limitations
Small, single-center study; groups allocated by treatment rather than randomized. Composite response mixes different outcomes; no separate pregnancy or live-birth result.
Clinical observation of Tiaojing Cuyun Pills combined with dydrogesterone in treatment of infertility due to luteal insufficiency. https://www.tiprpress.com/xdywlc/article/pdf/xdywylc20190349
Study type: clinical_trial
-
[2]Meta-analysis of Tiaojing Cuyun Wan combined with Western medicine for infertility associated with obesity-related polycystic ovary syndrome
Population: Women with obesity, polycystic ovary syndrome and infertility
Indication: Infertility associated with obesity and PCOS
Intervention: Tiaojing Cuyun Pills added to conventional medicines; regimens varied
Comparison: Corresponding conventional medicines without Tiaojing Cuyun Pills
Sample size: 1482 across 15 trials
Duration: Varied; individual treatment durations unavailable in accessible abstract
Reported findings
Adding Tiaojing Cuyun Pills to conventional medicines was associated with higher pregnancy and ovulation rates than conventional medicines alone. Endometrial thickness and adverse-event rates did not differ significantly.
Interpretation
Pooled adjunctive-treatment findings do not establish benefit when this medicine is used alone or a general indication for PCOS.
Limitations
Abstract-level appraisal; heterogeneous conventional regimens and underlying trial quality. Some constituent reports contain reporting inconsistencies. No demonstrated live-birth outcome in the accessible abstract; overlap with other syntheses is possible.
调经促孕丸联合西药治疗肥胖型多囊卵巢综合征不孕症的Meta分析. https://szyx.cbpt.cnki.net/portal/journal/portal/client/paper/63726f5bf6be61846fa73465188ecd4a
Year: 2026
Study type: meta_analysis
-
[3]Network meta-analysis of Chinese patent medicines combined with clomiphene for ovulatory infertility
Population: Women with ovulatory infertility across trials of 12 Chinese patent medicines
Indication: Ovulatory infertility
Intervention: Tiaojingcuyun Pills plus clomiphene within a network of combination regimens
Comparison: Clomiphene and other Chinese patent medicine plus clomiphene regimens
Sample size: 2647 across all 30 trials and 12 medicines; target-specific sample size unavailable
Duration: Not reported in the accessible abstract
Reported findings
Tiaojingcuyun Pills plus clomiphene ranked highest for pregnancy rate among the regimens compared. Limited trial quality and indirect comparisons make that ranking uncertain.
Interpretation
Accepted under the benchmark’s explicit tiaojingcuyun alias rule. A network ranking is not proof of superiority or a result from 2647 target-treated patients.
Limitations
Abstract-level appraisal; indirect comparisons and limited trial quality. Target-specific effect estimate and sample size unavailable. Trial overlap with other reviews must not be counted as independent participants.
Network meta-analysis of Chinese patent medicines combined with clomiphene for ovulatory infertility. https://hnyy.cbpt.cnki.net/portal/journal/portal/client/paper/3c75482309f96d762506bc4d37ead497
Year: 2024
Study type: meta_analysis